Organoids are an important component of translational research, particularly for evaluating drug toxicity and tissue-specific responses.

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...

Nader Z. Pourhassan, PhD, the former CEO of CytoDyn, was sentenced yesterday to 30 months in prison, more than a year after he was convicted on charges that included four counts of securities fraud, ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

Bacteria are present inside the most common type of kidney stone, revealing a previously unrecognized component involved in their formation.

WuXi Biologics says the company will provide the partnership with integrated, end-to-end biologics development and manufacturing services.

The Golden Gate Assembly platform engineers bacteriophages synthetically using sequence data rather than bacteriophage isolates.

Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.

MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

A team at Johns Hopkins Medicine has focused their work on myelin development using oligodendrocytes to help study conditions like MS.

The discovery fundamentally changes the understanding of a structure in the avian eye that has been misinterpreted for centuries.